• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by CymaBay Therapeutics Inc.

    3/22/24 4:55:49 PM ET
    $CBAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CBAY alert in real time by email
    S-8 POS 1 d808672ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 22, 2024

    Registration No. 333-272895

    Registration No. 333-273887

    Registration No. 333-195211

    Registration No. 333-198289

    Registration No. 333-202941

    Registration No. 333-210453

    Registration No. 333-216905

    Registration No. 333-223687

    Registration No. 333-226741

    Registration No. 333-229953

    Registration No. 333-254697

    Registration No. 333-263644

    Registration No. 333-270795

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

    REGISTRATION STATEMENTS

    NOS. 333-272895, 333-273887

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8

    REGISTRATION STATEMENTS

    NOS. 333-195211, 333-198289, 333-202941, 333-210453, 333-216905, 333-223687, 333-226741, 333-229953, 333-254697, 333-263644, 333-270795

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CYMABAY THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   94-3103561
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    7601 Dumbarton Circle

    Fremont, CA

      94555
    (Address of Principal Executive Offices)   (Zip Code)

    (510) 293-8800

    (Registrant’s telephone number, including area code)

    CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan

    CymaBay Therapeutics, Inc. 2023 Equity Incentive Plan

    2020 New Hire Plan

    (Full title of the plans)

    Paul Quinlan

    General Counsel

    CymaBay Therapeutics, Inc.

    7601 Dumbarton Circle

    Fremont, CA 94555

    (510) 293-8800

    (Name and address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Richard Hall

    Matthew L. Ploszek

    Cravath, Swaine & Moore LLP

    Worldwide Plaza

    825 Eighth Avenue

    New York, New York 10019

    (212) 474-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☒
         Emerging Growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    CymaBay Therapeutics, Inc., a Delaware corporation (the “Registrant”), is filing these Post-Effective Amendments (these “Post-Effective Amendments”) to the following Registration Statements on Form S-8 (each, a “Registration Statement” and, collectively, the “Registration Statements”), previously filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”), to deregister any and all shares of the Registrant’s common stock, par value $0.0001 per share (the “Common Stock”), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-195211), which was filed with the SEC on April  11, 2014, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,049,716 shares of Common Stock in the aggregate under the Metabolex, Inc. 2003 Equity Incentive Plan, the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan (the “2013 Plan”) and the CymaBay Therapeutics, Inc. 2023 Equity Incentive Plan (the “2023 Plan”);

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-198289), which was filed with the SEC on August  21, 2014, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 500,000 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-202941), which was filed with the SEC on March  23, 2015, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 734,805 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-210453), which was filed with the SEC on March  29, 2016, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,172,350 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-216905), which was filed with the SEC on March  23, 2017, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,172,350 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-223687), which was filed with the SEC on March  15, 2018, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 2,220,439 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-226741), which was filed with the SEC on August  9, 2018, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,500,000 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-229953), which was filed with the SEC on February  28, 2019, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 2,378,259 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-254697), which was filed with the SEC on March  25, 2021, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 3,507,843 shares of Common Stock in the aggregate under the 2013 Plan, the 2020 New Hire Plan (the “2020 Plan”) and the 2023 Plan;


      •  

    Registration Statement on Form S-8 (Registration File No. 333-263644), which was filed with the SEC on March  17, 2022, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 4,233,896 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-270795), which was filed with the SEC on March  23, 2023, as amended by that certain Post-Effective Amendment No. 1, which was filed with the SEC on August 10, 2023, pertaining to the registration of 4,234,053 shares of Common Stock under the 2013 Plan and the 2023 Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-272895), which was filed with the SEC on June 23, 2023, pertaining to the registration of 6,000,000 shares of Common Stock under the 2023 Plan; and

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-273887), which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,000,000 shares of Common Stock under the 2020 Plan.

    On February 11, 2024, the Registrant entered into that certain Agreement and Plan of Merger with Gilead Sciences, Inc., a Delaware corporation (“Parent”), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), pursuant to which, among other things, Purchaser merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. The Merger became effective on March 22, 2024, pursuant to a certificate of merger filed with the Secretary of State of the State of Delaware.

    In connection with the Merger, the Registrant has terminated any and all of the offerings of the Registrant’s securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold at the termination of the offerings, the Registrant hereby amends the Registration Statements and removes from registration any and all of the securities of the Registrant registered under the Registration Statements that remain unsold as of the date hereof, and hereby terminates the effectiveness of each of the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, California, on March 22, 2024.

     

    CymaBay Therapeutics, Inc.
    By:  

    /s/ Paul Quinlan

    Name:   Paul Quinlan
    Title:   General Counsel

     

    *

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.

    Get the next $CBAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBAY

    DatePrice TargetRatingAnalyst
    2/13/2024Outperform → Mkt Perform
    Raymond James
    8/14/2023$18.00Buy
    UBS
    8/11/2023$20.00Buy
    Guggenheim
    4/5/2023Outperform
    William Blair
    3/9/2023$15.00Buy
    BTIG Research
    4/11/2022$9.00Overweight
    Cantor Fitzgerald
    11/11/2021$12.00 → $14.00Strong Buy
    Raymond James
    8/3/2021$13.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CBAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CymaBay Therapeutics downgraded by Raymond James

      Raymond James downgraded CymaBay Therapeutics from Outperform to Mkt Perform

      2/13/24 6:29:47 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on CymaBay Therapeutics with a new price target

      UBS initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $18.00

      8/14/23 7:12:38 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on CymaBay Therapeutics with a new price target

      Guggenheim initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $20.00

      8/11/23 7:12:36 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    SEC Filings

    See more
    • SEC Form 15-12G filed by CymaBay Therapeutics Inc.

      15-12G - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      4/1/24 6:04:16 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:07 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:28 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/24 4:46:08 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/24 4:05:38 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/24 9:09:24 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead Sciences Announces Completion of Acquisition of CymaBay

      Acquisition Reinforces Gilead's Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (NASDAQ:GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (NASDAQ:CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients. "The acquisition of CymaBay brings us a potential best in disease therapy that

      3/22/24 9:18:00 AM ET
      $CBAY
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

      NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency (EMA). Seladelpar is an investigational, potent, selective peroxisome proliferator-activated receptor delta (PPARδ)

      3/4/24 8:00:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Loewy Caroline M

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:09:21 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mcwherter Charles returned 46,938 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:06:11 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lefebvre Eric

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:05:48 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

      NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as President of Research and Development. "We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer. Chuck joined CymaBay in 2007 and has served as Chief Scientific Officer since 2013. In this role he has been instrumental in the development of seladelpar. Chuck's extensive experience in the pharmaceutical industry

      11/1/22 8:01:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors

      NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors. "We are excited to be welcoming Éric to the Board. Éric's extensive experience in the pharmaceutical industry as an executive focused on clinical development, medical affairs, business development and life-cycle strategy and more than 10 years of experience developing drugs in liver disease indications make him a perfect addition to our Board. We look forward to Éric helping guide us thr

      3/17/22 4:25:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC

      Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity

      8/14/24 12:53:53 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBAY
    Financials

    Live finance-specific insights

    See more
    • CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

      Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera

      2/28/24 4:45:25 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

      NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 1-877-407-0784 from the U.S. and Canada, or 1-201-689-8560 internationally, Conference ID #13740701. To access the live and subsequently archived webcast of the conference call, go t

      10/31/23 4:05:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis

      Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) Normalization of alkaline phosphatase at 12 months was achieved by 25.0% of patients treated with seladelpar vs. 0% on placebo (p<0.0001) In patients having moderate-to-severe itch at baseline, the seladelpar treated group improved their pruritus at 6 months compared to those in the placebo group (p<0.005) Safety and tolerability were comparable between placebo and seladelpar groups and consistent with previous studies CymaBay will hold a conference call to discuss these results today at 8:00 a.m. ET N

      9/7/23 7:00:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care